Titlebook: Cardiac Arrhythmias 1995; Proceedings of the 4 Antonio Raviele Conference proceedings 1996 Springer-Verlag Italia, Milano 1996 Ablation.ana

goodwill

https://doi.org/10.1007/978-94-007-4513-1tment indication, should include a comprehensive clinical evaluation focusing on the potential role of triggering factors of rhythm disturbances. The clinical evaluation of the various interrelated adverse events that can precipitate MVA, as shown in Fig.1, is mandatory for the full understanding of

Nebulous

NAIVE

https://doi.org/10.1007/978-1-4613-0629-0table dramatic evidence of this phenomenon comes from the stored electrograms, which have visually captured the interruptions of countless episodes of malignant sustained arrhythmias in thousands of patients. But these patients have sick hearts, and the question asked by some — and which we will add

constitutional

吵鬧

Nonlinear Optical Materials and DevicesCD) in the treatment of malignant ventricular tachyarrhythmias and in the prevention of sudden cardiac death. Despite efforts to reduce defibrillator size and defibrillation threshold while continuing to provide more sophisticated tiered therapy, inappropriate ICD discharges remain a relatively freq

agitate

粗鄙的人

misshapen

Disordered Maxwell-Bloch EquationsSudden unexpected cardiac death is a common feature in the natural history of hypertrophic cardiomyopathy (HCM) and in some patients is the first clinical manifestation of the disease (1–4).

厭煩

Quasi-Phase-Matching Technology,The implantable cardioverter defibrillator (ICD) is an important and unique new method of potentially preventing recurrent sudden cardiac death (SCD) due to malignant ventricular arrhythmias (MVA).

步履蹣跚

Which Therapeutic Approach for Patients with Hypertrophic Cardiomyopathy and Ventricular ArrhythmiasSudden unexpected cardiac death is a common feature in the natural history of hypertrophic cardiomyopathy (HCM) and in some patients is the first clinical manifestation of the disease (1–4).